Sign up now!
Don't show this again
Tap to download the app
X
Share
X

REPORTS

Collect articles and features into your own report to read later, print or share with others

Create a New Report

Favorites

Read Later

Create a new report

Report title (required) Brief description (optional)
CREATE
X
NEXT
PORK POULTRY
follow us


You must be logged in to edit your profile.

Favorites Read Later My Reports PHT Special Reports
Pig Health Today is equipped with some amazing (and free) tools for organizing and sharing content, as well as creating your own magazines and special reports. To access them, please register today.
Sponsored by Zoetis

Pig Health Today | Sponsored by Zoetis

.

Our strategy for eliminating M. hyo from breed-to-wean herds

Photo above courtesy of National Pork Board

By Attila Farkas, DVM
Carthage Veterinary Service, Ltd.
Carthage, Illinois

Many pork producers still struggle with Mycoplasma hyopneumonia (M. hyo) in their herds. The pathogen remains one of the prevailing causes of enzootic pneumonia. Even though it’s primarily a chronic respiratory disease of growers, M. hyo can also affect young and adult pigs, especially in recently affected herds.

Most of us in the industry have seen the clinical manifestations of M. hyo disease. There’s usually a persistent, nonproductive cough. Affected herds also have reduced average daily gain, poor feed conversion, high morbidity, low mortality and increased medication cost.

What is it about M. hyo that makes it so costly? M. hyo adheres to the ciliary epithelia in the upper repiratory tract. The result is ciliostasis — the cilia can’t move normally — which interferes with mucin production. This increases the pig’s susceptibility to viral pathogens such as swine influenza virus, as well as bacterial pathogens such as Streptococcus suis, Haemophilus parasuis and others involved in porcine respiratory disease complex.

In a large US production system, the cost of uncomplicated M. hyo infection over a 4-year period has been estimated to be less than US $1 per pig. However, when pigs with M. hyo were co-infected with swine influenza virus or porcine reproductive and respiratory syndrome (PRRS) virus, the economic toll is about $10 per pig.1

Swine veterinarians and producers have attempted to mitigate economic losses from M. hyo with a variety of strategies such as depopulation and repopulation, partial depopulation, whole-herd medication without closure, herd closure and individualized medication — all of which have brought varying degrees of success.

At our practice, we’ve been able to successfully help producers eliminate M. hyo from breed-to-wean herds with the following approach:

First steps

  • Profile the herd by collecting serum samples from across multiple ages. This helps establish herd-exposure status and prevalence.
  • Remove younger animals that have not seroconverted to M. hyo.
  • Close the herd to new gilts.

Post herd closure (PHC)

  • 1 week PHC — Initiate whole-herd vaccination (boars, sows, gilts and piglets) with a commercial M. hyo bacterin to maximize immunity throughout the population.
  • 25 weeks PHC — Vaccinate the sow unit and gilt-developer unit with a commercial M. hyo bacterin.
  • 28 weeks PHC — Re‐vaccinate all animals in the sow unit and gilt-developer unit with a commercial M. hyo bacterin to bolster herd immunity.
  • 31 weeks PHC — Administer Draxxin® 25 injectable solution (tulathromycin) to all pigs at birth and the pigs aged 1 to 9 days old in the farrowing house. Continue injecting pigs at birth and at 10 days of age with the same injectable Draxxin 25 for 3 consecutive weeks. Draxxin 25 injectable provides therapeutic levels for up to 9 days in lung tissues.2
  • 33 weeks PHC — Provide medicated feed to the whole herd. Choose a product with appropriate labeling for M. hyo management, follow label directions and medicate boars, sows and gilts for 3 consecutive weeks.  During this period of medicated feed, administer Draxxin injectable solution to sows and boars that are sick or off feed.
  • 36 weeks PHC — Collect laryngeal swabs from wean piglets and deep tracheal swabs
    from sows and gilts. Test for M. hyo by polymerase chain reaction (PCR). Recommendations on sample size are listed in Table 2.
  • 37 weeks PHC — If you have negative M. hyo results by PCR on the laryngeal swabs collected from wean pigs and deep tracheal swabs collected from sows, open the herd to naïve replacement gilts.
  • 1 month after the first M. hyonegative gilts are introduced — Initiate monthly serological testing of replacement gilts. Recommendations on sample size are listed in Table 2.

Determine success

In 2016, Lucina Galina, DVM, Zoetis, and Maria Clavijo, DVM, University of Minnesota, proposed M. hyo classification criteria for breeding herds (Table 1).3  The purpose of the classification system was to facilitate communication between swine producers, veterinarians, diagnosticians and breeding-stock companies that are evaluating disease-control strategies and to support regional control and elimination efforts,² but we’ve found the system is also a useful tool for measuring M. hyo-elimination success.

It’s important to remember that elimination does not prevent re‐infection. Biosecurity procedures must be  kept in place to prevent reccurring infections and the spread of M. hyo and other potential swine pathogens.

Preventive measures can make the difference between success or setbacks in time, money and production. Moreover, to maintain a healthy herd, disease prevention should be an active and ongoing process.

Table 1. M. hyo breeding-herd-status classification criteria*2    

Herd Category Criteria Description and Diagnostic Requirements
Clinical Signs Antigen Detection in Respiratory Tract Serology
Positive unstable

(I)

Yes Yes Maybe Clinical signs consistent with M. hyo are present and M. hyo is detected within lesions and/or in the respiratory tract.

Recently infected populations may be serologically negative.

Untested herds are category I by default.

Positive stable

(II)

No Yes

<10% of weaning-age pigs positive for antigen within respiratory tract

Yes M. hyo characteristic clinical signs or lesions are not detected.

At least 90 days of less than 10% of due-to-be-weaned pigs positive by PCR in 4 consecutive samplings of 45 laryngeal swabs at days 0, 30, 60 and 90.*

Provisionally negative

(III)

No No Yes At least 90 days of negative results from weaning-age pigs by PCR in 4 consecutive samplings of 30 laryngeal swabs at days 0, 30, 60 and 90.*

Herds undergoing M. hyo elimination, no clinical signs or positive tests from respiratory tract of replacement animals, at least 60 days after the initial introduction.

Negative but vaccinated herds are considered category III.

Negative

(IV)

No No No At least 1 year as category III and have gone through a complete sow rollover. At completion of rollover testing must take place.

Newly established herds and herds that underwent complete depopulation and repopulation.

A minimum of 30 serum samples from sows should test negative by ELISA.*

*http://epitools.ausvet.com/au/content.php?page=PrevalenceSS. Accessed December 2015.

  

 

Table 2. Recommended number of diagnostic samples based on population size

Population Size Required to Detect
1200 2400 3600 4800 6000
True Prevalence 1% 264 280 286 289 291
5% 57 58 58 58 58
10% 28 28 28 28 28
15% 18 18 18 18 18
20% 13 13 13 13 13
25% 10 10 10 10 10

*All calculations assume a 5% confidence (Z beta error)

 

 

IMPORTANT SAFETY INFORMATION: Withdraw DRAXXIN/DRAXXIN 25 five (5) days prior to slaughter. Do not use in animals known to be hypersensitive to the product.

Click here for DRAXXIN Prescribing Information.   Click here for DRAXXIN 25 Prescribing Information.

 

 

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

 

 

1. Haden CD, et al. Assessing production parameters and economic impact of swine influenza, PRRS, and Mycoplasma hyopneumoniae on finishing pigs in a large production system. Proc AASV. Denver, Colorado. 2012;75‐76
2. Senn MK, et al. Evaluation of DRAXXIN® Injectable Solution for the control of swine respiratory disease. AASV. 2010;143-146
3. Galina L, Clavijo MJ. Establishing Mycoplasma hyopneumoniae herd status classification criteria for breeding herds. AASV. 2016;167‐169

 

 

 

 

 

DXS-00038


tags: ,
RELATED NEWS
  • New claim provides flexible dosing for M. hyo. medication

    Pork producers battling swine respiratory disease associated with Mycoplasma hyopneumoniae (M. hyo) now have more flexibility when using Lincomix® (lincomycin hydrochloride) Type A medicated article.

  • New claim provides flexible dosing for M. hyo medication

    Pork producers battling swine respiratory disease associated with Mycoplasma hyopneumoniae (M. hyo) now have more flexibility when using Lincomix® (lincomycin hydrochloride) Type A medicated article, thanks to a new dosing level approved by the U.S. Food and Drug...

  • Mycoplasma hyopneumoniae: Elimination or control?

    By Clayton Johnson, DVM Carthage Veterinary Service Integrated Veterinary Network

  • Mycoplasma hyopneumoniae: ‘Fix the gilts, fix Mycoplasma’

    There’s a lot we think we know about M. hyo under field conditions, but there’s a paucity of peer-reviewed literature to support much of the conventional wisdom we swine veterinarians apply to its management, well as its role in PRDC.




You must be logged in to edit your profile.

Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.